Nocturnal HHHFA over 6 weeks did not improve clinical or imaging outcomes in this small cohort of COPD patients with chronic bronchitis, though the study was likely underpowered due to recruitment challenges.
The study enrolled very few participants, with only 7 of 11 eligible participants completing the trial.
No statistically significant differences were observed between the HHHFA and usual care groups in any primary or secondary outcomes.
Baseline characteristics between the intervention and control groups were not fully matched, with notable differences in BMI and emphysema percentage.
The study design was a prospective, single-center, open-label, randomized, placebo-controlled trial targeting COPD patients with chronic bronchitis and frequent exacerbations.
The authors concluded that larger trials are needed to properly assess the potential of HHHFA in COPD patients with chronic bronchitis.
This research suggests that a breathing treatment called heated, humidified high-flow air (HHHFA), delivered at night through a nasal cannula, did not show measurable benefits over 6 weeks in a very small group of COPD patients who also had chronic bronchitis (a condition involving persistent mucus production and coughing). The study measured a wide range of outcomes including sleep quality, breathlessness, quality of life, cough, lung function, imaging results, and exercise capacity, and found no statistically significant improvements in the group receiving the treatment compared to those receiving usual care. However, the study was extremely small — only 7 people finished the trial out of 11 who were eligible — which means it almost certainly did not have enough participants to reliably detect a real effect if one existed. This limitation, known as being 'underpowered,' is a major caveat when interpreting the results. There were also some baseline differences between the two groups, such as differences in body weight and the extent of emphysema in their lungs, which could have influenced the findings. This research suggests that while this pilot study could not confirm a benefit of HHHFA for this specific group of COPD patients, the question remains open. The treatment has shown promise in related conditions, and the authors call for larger, better-powered clinical trials to properly evaluate whether HHHFA could help COPD patients with chronic bronchitis reduce symptoms or improve their quality of life.
Fortis S, Hoffman E, Comellas A. (2026). The Effect of Heated, Humidified High-Flow Air in COPD Patients With Chronic Bronchitis.. Pulmonary medicine. https://doi.org/10.1155/pm/8350741